Amgen, Inc. (NASDAQ:AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide …
Amgen, Inc. (NASDAQ:AMGN) announced a neuroscience collaboration with Novartis in the areas of Alzheimer’s disease and migraine.
Amgen, Inc. (NASDAQ:AMGN) and UCB announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with his views on Amgen, Inc. (NASDAQ:AMGN), following the news that the company received FDA approval for its PCSK9 inhibitor …
Amgen, Inc. (NASDAQ:AMGN) announced that the U.
Amgen, Inc. (NASDAQ:AMGN) announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for etelcalcetide (formerly …
Many investors were on edge this weekend after the stock market plummeted on Thursday due to China’s faltering stock market and concerns that …
Amgen, Inc. (NASDAQ:AMGN) and the Center for Social Sector Leadership at the University of California (UC), Berkeley’s Haas School of Business today announced a …
Nomura Holdings analyst Ian Somaiya came out with some commentary on Amgen Inc. (NASDAQ:AMGN) following an FDA panel recommendation for the company’s drug Repatha, …
One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …
